Codiak BioSciences, Inc. (CDAK)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Douglas E. Williams
Employees:
C/O ARCH VENTURE PARTNERS, 999 THIRD AVENUE, SUITE 3400, SEATTLE, WA 98104
857-400-4222

Codiak BioSciences, Inc. is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need.

Data derived from most recent annual or quarterly report
Market Cap 87.501 Million Shares Outstanding22.494 Million Avg 30-day Volume 240.659 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-12.83
Price to Revenue10.9257 Debt to Equity0.4753 EBITDA-29.142 Million
Price to Book Value4.6833 Operating Margin-303.24399999999997 Enterprise Value199.074 Million
Current Ratio3.319 EPS Growth0.895 Quick Ratio2.832
1 Yr BETA 1.513 52-week High/Low 22.95 / 2.21 Profit Margin-162.01
Operating Cash Flow Growth-17.0184 Altman Z-Score-1.4689 Free Cash Flow to Firm -99.963 Million
Earnings Report2022-08-04
View SEC Filings from CDAK instead.

View recent insider trading info

Funds Holding CDAK (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding CDAK BETA

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2022-06-21:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-03-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-11-30:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-11-17:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-11-16:
    Item 1.01: Entry into a Material Definitive Agreement
  • 8-K: filed on 2021-11-04:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-11-04:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-11-02:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-10-07:
    Item 1.02: Termination of a Material Definitive Agreement
  • 8-K: filed on 2021-09-21:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
  • Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    COONEY CHARLES L

    • Director
    9,000 2022-06-17 2

    MELAS KYRIAZI THEO

    • Director
    9,000 2022-06-17 2

    GILLIS STEVEN

    • Director
    9,000 2022-06-17 2

    BERNSTEIN KAREN

    • Director
    1,500 2022-06-17 2

    HADDOCK JASON

    • Director
    9,000 2022-06-17 2

    PANDITE ARUNDATHY N.

    • Director
    9,000 2022-06-17 3

    EGGIMANN ANNE-VIRGINIE

    • Director
    9,000 2022-06-17 1

    MAURO DAVID J CHIEF MEDICAL OFFICER

    • Officer
    0 2022-05-02 2

    WILLIAMS DOUGLAS E PRESIDENT & CEO

    • Officer
    • Director
    153,125 2022-02-16 2

    BAIN LINDA CHIEF FINANCIAL OFFICER

    • Officer
    50,750 2022-02-16 2

    BRUDNICK RICHARD SEE REMARKS

    • Officer
    27,125 2022-02-16 2

    KONSTANTINOV KONSTANTIN CHIEF TECHNOLOGY OFFICER

    • Officer
    28,000 2022-02-16 2

    BARNA NICOLE SEE REMARKS

    • Officer
    21,000 2022-02-16 3

    HOWZE YALONDA SEE REMARKS

    • Officer
    32,375 2022-02-16 2

    SATHYANARAYANAN SRIRAM CHIEF SCIENTIFIC OFFICER

    • Officer
    49,000 2022-02-16 3

    SORENSEN BENNY SEE REMARKS

    • Officer
    87,411 2021-06-08 0

    WHELER JENNIFER J. CHIEF MEDICAL OFFICER

    • Officer
    100,000 2021-05-10 0

    MORRISON BRIGGS

    • Director
    4,761 2021-02-17 0

    VERMA AJAY SEE REMARKS

    • Officer
    0 2021-01-22 0

    ARCH VENTURE FUND VIII, L.P.

    ARCH VENTURE FUND VIII OVERAGE, L.P.

    CRANDELL KEITH

    BYBEE CLINTON

    NELSEN ROBERT

    ARCH VENTURE PARTNERS VIII, LLC

    ARCH VENTURE PARTNERS VIII, L.P.

    • 10% Owner
    3,854,098 2020-10-16 0

    FLAGSHIP VENTURES FUND V GENERAL PARTNER LLC

    FLAGSHIP VENTURES FUND V, L.P.

    FLAGSHIP V VENTURELABS RX FUND, L.P.

    AFEYAN NOUBAR

    • 10% Owner
    2,607,303 2020-10-16 0

    ALASKA PERMANENT FUND CORP

    18,051,580 2020-10-16 0

    LANDER ERIC S

    • Director
    738,134 2020-10-13 0

    FLAGSHIP VENTURES FUND V GENERAL PARTNER LLC

    FLAGSHIP VENTURELABS V LLC

    FLAGSHIP VENTURELABS V MANAGER LLC

    FLAGSHIP PIONEERING INC.

    FLAGSHIP VENTURES FUND V, L.P.

    FLAGSHIP V VENTURELABS RX FUND, L.P.

    AFEYAN NOUBAR

    • 10% Owner
    485,949 2020-10-13 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    PANDITE ARUNDATHY N. - Director

    2022-06-21 16:43:37 -0400 2022-06-17 A 7,500 a 7,500 direct

    PANDITE ARUNDATHY N. - Director

    2022-06-21 16:43:37 -0400 2022-06-17 A 1,500 a 1,500 direct

    MELAS KYRIAZI THEO - Director

    2022-06-21 16:47:41 -0400 2022-06-17 A 7,500 a 7,500 direct

    MELAS KYRIAZI THEO - Director

    2022-06-21 16:47:41 -0400 2022-06-17 A 1,500 a 1,500 direct

    COONEY CHARLES L - Director

    2022-06-21 16:47:27 -0400 2022-06-17 A 7,500 a 7,500 direct

    COONEY CHARLES L - Director

    2022-06-21 16:47:27 -0400 2022-06-17 A 1,500 a 1,500 direct

    GILLIS STEVEN - Director

    2022-06-21 16:45:26 -0400 2022-06-17 A 7,500 a 7,500 direct

    GILLIS STEVEN - Director

    2022-06-21 16:45:26 -0400 2022-06-17 A 1,500 a 1,500 direct

    BERNSTEIN KAREN - Director see footnote

    2022-06-21 16:48:27 -0400 2022-06-17 A 7,500 a 7,500 indirect

    BERNSTEIN KAREN - Director see footnote

    2022-06-21 16:48:27 -0400 2022-06-17 A 1,500 a 1,500 indirect

    EGGIMANN ANNE-VIRGINIE - Director

    2022-06-21 16:48:01 -0400 2022-06-17 A 7,500 a 7,500 direct

    EGGIMANN ANNE-VIRGINIE - Director

    2022-06-21 16:48:01 -0400 2022-06-17 A 1,500 a 1,500 direct

    HADDOCK JASON - Director

    2022-06-21 16:51:49 -0400 2022-06-17 A 7,500 a 7,500 direct

    HADDOCK JASON - Director

    2022-06-21 16:51:49 -0400 2022-06-17 A 1,500 a 1,500 direct

    MAURO DAVID J - Officer CHIEF MEDICAL OFFICER

    2022-05-04 16:29:09 -0400 2022-05-02 A 200,000 a 200,000 direct

    MAURO DAVID J - Officer CHIEF MEDICAL OFFICER

    2022-05-04 16:29:09 -0400 2022-05-02 A 20,000 a 20,000 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    CODIAK BIOSCIENCES INC CDAK 2022-06-24 22:15:03 UTC 0.167 1.403 300000
    CODIAK BIOSCIENCES INC CDAK 2022-06-24 21:45:03 UTC 0.167 1.403 300000
    CODIAK BIOSCIENCES INC CDAK 2022-06-24 21:15:04 UTC 0.167 1.403 300000
    CODIAK BIOSCIENCES INC CDAK 2022-06-24 20:45:03 UTC 0.1123 1.4577 300000
    CODIAK BIOSCIENCES INC CDAK 2022-06-24 20:15:03 UTC 0.1123 1.4577 300000
    CODIAK BIOSCIENCES INC CDAK 2022-06-24 19:45:03 UTC 0.1123 1.4577 300000
    CODIAK BIOSCIENCES INC CDAK 2022-06-24 19:15:03 UTC 0.1123 1.4577 300000
    CODIAK BIOSCIENCES INC CDAK 2022-06-24 18:45:03 UTC 0.0373 1.5327 300000
    CODIAK BIOSCIENCES INC CDAK 2022-06-24 18:15:04 UTC 0.0373 1.5327 300000
    CODIAK BIOSCIENCES INC CDAK 2022-06-24 17:45:03 UTC 0.0373 1.5327 300000
    CODIAK BIOSCIENCES INC CDAK 2022-06-24 17:15:03 UTC 0.0373 1.5327 300000
    CODIAK BIOSCIENCES INC CDAK 2022-06-24 16:45:03 UTC 0.0373 1.5327 300000
    CODIAK BIOSCIENCES INC CDAK 2022-06-24 16:15:03 UTC 0.0373 1.5327 300000
    CODIAK BIOSCIENCES INC CDAK 2022-06-24 15:45:03 UTC 0.0373 1.5327 10000
    CODIAK BIOSCIENCES INC CDAK 2022-06-24 15:15:03 UTC 0.0373 1.5327 6000
    CODIAK BIOSCIENCES INC CDAK 2022-06-24 14:45:03 UTC 0.5702 0.9998 6000
    CODIAK BIOSCIENCES INC CDAK 2022-06-24 14:15:03 UTC 0.5702 0.9998 6000
    CODIAK BIOSCIENCES INC CDAK 2022-06-24 13:45:03 UTC 0.5702 0.9998 6000
    CODIAK BIOSCIENCES INC CDAK 2022-06-24 13:15:03 UTC 0.5702 0.9998 6000
    CODIAK BIOSCIENCES INC CDAK 2022-06-24 12:45:03 UTC 0.5702 0.9998 6000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund CDAK -300.0 shares, $-1881.0 2022-03-31 N-PORT

    Elevate your investments